Overview Financials News + Filings Key Docs Charts Transactions Holdings Ownership Insiders
|
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Minimum | | | | | | | 2,334.4 | |
| Jardiance | | | | | | | 201.9 | |
| Basaglar | | | | | | | 86.1 | |
| Maximum | | | | | | | 3,607.8 | |
| Other | | | | | | | 14,991.9 | |
| Total revenues | 28,541.4 | 28,318.4 | 24,539.8 | 22,319.5 | 21,493.3 | 19,973.8 | 21,222.1 | 19,958.7 |
| Revenue growth [+] | 0.8% | 15.4% | 9.9% | 3.8% | 7.6% | -5.9% | 6.3% | 1.7% |
| Human Pharmaceutical Products | | | | | | | -97.3% | -2.8% |
| Cost of goods sold | 6,629.8 | 7,312.8 | 5,483.3 | 4,721.2 | 4,681.7 | 4,447.7 | 5,710.1 | 5,037.2 |
| Gross profit | 21,911.6 | 21,005.6 | 19,056.5 | 17,598.3 | 16,811.6 | 15,526.1 | 15,512.0 | 14,921.5 |
| Gross margin | 76.8% | 74.2% | 77.7% | 78.8% | 78.2% | 77.7% | 73.1% | 74.8% |
| Selling, general and administrative | 6,440.4 | 6,431.6 | 6,121.2 | 6,213.8 | 5,975.1 | 5,982.4 | 6,528.0 | 6,533.0 |
| Research and development | 7,190.8 | 6,930.7 | 5,976.3 | 5,595.0 | 5,051.2 | 5,096.2 | 5,310.3 | 4,796.4 |
| Other operating expenses | 908.5 | 970.1 | 769.8 | | | | | |
| EBITDA [+] | 8,894.4 | 8,220.8 | 7,513.1 | 7,022.1 | 7,394.3 | 6,014.8 | 5,170.3 | 5,019.8 |
| EBITDA growth | 8.2% | 9.4% | 7.0% | -5.0% | 22.9% | 16.3% | 3.0% | 6.6% |
| EBITDA margin | 31.2% | 29.0% | 30.6% | 31.5% | 34.4% | 30.1% | 24.4% | 25.2% |
| Depreciation | 942.8 | 918.8 | 895.7 | 1,006.8 | 1,247.7 | 1,105.1 | 808.7 | 795.9 |
| EBITA | 7,951.6 | 7,302.0 | 6,617.4 | 6,015.3 | 6,146.6 | 4,909.7 | 4,361.6 | 4,223.9 |
| EBITA margin | 27.9% | 25.8% | 27.0% | 27.0% | 28.6% | 24.6% | 20.6% | 21.2% |
| Amortization of intangibles | 579.7 | 628.8 | 428.2 | 225.8 | 361.3 | 462.2 | 687.9 | 631.8 |
| EBIT [+] | 7,371.9 | 6,673.2 | 6,189.2 | 5,789.5 | 5,785.3 | 4,447.5 | 3,673.7 | 3,592.1 |
| EBIT growth | 10.5% | 7.8% | 6.9% | 0.1% | 30.1% | 21.1% | 2.3% | 7.9% |
| EBIT margin | 25.8% | 23.6% | 25.2% | 25.9% | 26.9% | 22.3% | 17.3% | 18.0% |
| Non-recurring items [+] | 244.6 | 316.1 | 131.2 | 815.2 | 2,250.8 | 2,444.2 | 412.5 | 902.7 |
| Asset impairment | 244.6 | 316.1 | 131.2 | 575.6 | 266.9 | 1,331.6 | 382.5 | 367.7 |
| In-process research & development | | | | 239.6 | 1,983.9 | 1,112.6 | 30.0 | 535.0 |
| Interest expense, net [+] | -62.8 | -25.4 | -33.0 | -80.4 | -159.3 | -166.4 | -108.7 | -87.0 |
| Interest expense | 331.6 | 339.8 | 359.6 | 400.6 | 242.5 | 225.0 | 185.2 | 161.2 |
| Interest income | 62.8 | 25.4 | 33.0 | 80.4 | 159.3 | 166.4 | 108.7 | 87.0 |
| Other income (expense), net | -52.1 | 112.8 | 1,498.5 | 611.8 | 228.8 | 360.1 | 189.3 | 174.8 |
| Pre-tax income | 6,806.4 | 6,155.5 | 7,229.9 | 5,265.9 | 3,680.1 | 2,304.8 | 3,374.0 | 2,790.0 |
| Income taxes | 561.6 | 573.8 | 1,036.2 | 628.0 | 529.5 | 2,391.2 | 636.4 | 381.6 |
| Tax rate | 8.3% | 9.3% | 14.3% | 11.9% | 14.4% | 103.7% | 18.9% | 13.7% |
| Earnings from continuing ops | 6,244.8 | 5,581.7 | 6,193.7 | 957.4 | 3,069.2 | 31.3 | 2,737.6 | 2,408.4 |
| Earnings from discontinued ops | | | | 3,680.5 | 81.4 | -117.7 | | |
| Net income | 6,244.8 | 5,581.7 | 6,193.7 | 4,637.9 | 3,150.6 | -86.4 | 2,737.6 | 2,408.4 |
| Net margin | 21.9% | 19.7% | 25.2% | 20.8% | 14.7% | -0.4% | 12.9% | 12.1% |
| |
| Basic EPS [+] | $6.93 | $6.15 | $6.82 | $1.03 | $2.99 | $0.03 | $2.59 | $2.27 |
| Growth | 12.5% | -9.8% | 563.6% | -65.6% | 9937.6% | -98.8% | 14.1% | 1.5% |
| Diluted EPS [+] | $6.90 | $6.12 | $6.79 | $1.02 | $2.97 | $0.03 | $2.58 | $2.26 |
| Growth | 12.8% | -9.8% | 563.4% | -65.5% | 9879.9% | -98.8% | 14.1% | 1.6% |
| |
| Dividends per share [+] | $4.07 | $3.53 | $3.07 | $2.68 | $2.33 | $2.12 | $2.05 | $2.00 |
| Growth | 15.3% | 15.0% | 14.6% | 15.0% | 9.9% | 3.4% | 2.3% | 2.0% |
| |
| Shares outstanding (basic) [+] | 901.7 | 907.0 | 907.6 | 931.1 | 1,027.7 | 1,052.0 | 1,058.3 | 1,061.9 |
| Growth | -0.6% | -0.1% | -2.5% | -9.4% | -2.3% | -0.6% | -0.3% | -0.7% |
| Shares outstanding (diluted) [+] | 904.6 | 911.7 | 912.5 | 935.7 | 1,033.7 | 1,052.0 | 1,061.8 | 1,065.7 |
| Growth | -0.8% | -0.1% | -2.5% | -9.5% | -1.7% | -0.9% | -0.4% | -0.8% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|